ImaginAb Reconstitutes Scientific Advisory Board
ImaginAb Reconstitutes Scientific Advisory Board
Members include Immuno-Oncology leaders Dr. Antoni Ribas, Dr. Daniel D. Von Hoff and Dr. David Mankoff
LOS ANGELES, May 17, 2018 /PRNewswire/ -- ImaginAb Inc., an immuno-oncology imaging company, today announced the reconstitution of its Scientific Advisory Board (SAB) comprised of foremost global key opinion leaders in the development of anticancer therapies. The SAB will work closely with ImaginAb's management team to advance the development of ImaginAb's CD8 T Cell ImmunoPET, an imaging agent that has the potential to expedite the development of next-generation therapeutics.
The new members of the SAB are: Dr. Antoni Ribas, Dr. Daniel D. Von Hoff and Dr. David Mankoff. The Company is in discussions regarding the appointment of two additional members.
"We are honored to welcome these luminaries to our Scientific Advisory Board," said Martyn Coombs, CEO of ImaginAb. "Toni, Dan and David share our excitement about the potential of our products to change the way that patients with cancer are treated, as well our future goal of helping patients with auto-immune conditions. Their insight and advice will be invaluable as we develop our business strategy and work through collaborations with pharmaceutical companies."
-- Dr. Antoni Ribas: Antoni Ribas, M.D., Ph.D. is Professor of Medicine,
Professor of Surgery, and Professor of Molecular and Medical
Pharmacology at the University of California Los Angeles (UCLA),
Director of the Tumor Immunology Program at the Jonsson Comprehensive
Cancer Center (JCCC), Director of the Parker Institute for Cancer
Immunotherapy (PICI) Center at UCLA, and Chair of the Melanoma Committee
at SWOG. Dr Ribas is a physician-scientist who conducts laboratory and
clinical research in malignant melanoma, focusing on gene engineered T
cells, PD-1 blockade and BRAF targeted therapies. His National Cancer
Institute (NCI), State of California and private foundation-supported
research laboratory develops models of disease to test new therapeutic
options, studies mechanism of action of treatments in patients and the
molecular mechanisms of therapy resistance. Dr. Ribas is an elected
member of the American Society of Clinical Investigation (ASCI), has a
Doctor Honoris Causa from the University of Buenos Aires, the recipient
of the 2014 AACR Richard and Hinda Rosenthal Award, the 2018 AACR-CRI
Lloyd J. Old Award in Cancer Immunology and a NCI Outstanding
Investigator Award.
-- Dr. Daniel D. Von Hoff: Daniel D. Von Hoff, M.D., F.A.C.P., is currently
Physician in Chief, Distinguished Professor Translational Research at
TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He
is also Senior Consultant, Clinical Investigations for the City of Hope;
Chief Scientific Officer for HonorHealth Research Institute; Medical
Director of Research, Chief Scientific Officer, US Oncology, and
Professor of Medicine, Mayo Clinic. His major interest is in the
development of new anticancer agents, both in the clinic and in the
laboratory. At present, he and his colleagues are concentrating on the
development of molecularly targeted therapies for patients with
pancreatic and other advanced cancers. Dr. Von Hoff has published more
than 690 papers, 140 book chapters and over 1400 abstracts. He received
the 2010 David A. Karnofsky Memorial Award from the American Society of
Clinical Oncology for his outstanding contributions to cancer research
leading to significant improvement in patient care. He was previously
appointed to President Bush's National Cancer Advisory Board and is the
past President of the American Association for Cancer Research, a Fellow
of the American College of Physicians, and a member and past board
member of the American Society of Clinical Oncology. He is a founder of
ILEX Oncology, Inc. (acquired by Genzyme). Dr. Von Hoff is founder and
the Editor Emeritus of Investigational New Drugs - The Journal of New
Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer
Therapeutics and is a co-founder of the AACR/ASCO Methods in Clinical
Cancer Research Workshop.
-- Dr. David Mankoff: David Mankoff, M.D., Ph.D. is Gerd Muehllehner
Professor of Radiology, Vice-Chair for Research in Radiology, and
Director of the PET Center at the Perelman School of Medicine at the
University of Pennsylvania, where he has a special interest in oncologic
applications of molecular imaging and radionuclide treatment of
endocrine tumors and other cancers. He is board-certified in Nuclear
Medicine and holds a Ph.D. in Bioengineering focusing on PET
instrumentation. Dr. Mankoff's research focuses on molecular imaging of
cancer, primarily on breast cancer, and emphasizes therapeutic
monitoring, identifying factors mediating therapeutic resistance, and
the translation of new methods to clinical trials. Dr. Mankoff is a
Komen Scholar for the Susan G. Komen Foundation and Chairs the
Experimental Imaging Sciences Committee and serves as Co-Chair of the
Scientific Program Committee of ECOG-ACRIN. Dr. Mankoff is a past member
and President of the American Board of Nuclear Medicine, and is on the
editorial boards of numerous oncology and nuclear medicine publications.
About ImaginAb
ImaginAb Inc. is an immuno-oncology company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes, as well as developing a pipeline for other targets in oncology. ImaginAb's products have the potential to improve patient care and lower healthcare costs.
For more information please see www.imaginab.com.
Media contact:
Caroline V. Corner, PhD
Westwicke Partners
+1 415-202-5678
View original content with multimedia:http://www.prnewswire.com/news-releases/imaginab-reconstitutes-scientific-advisory-board-300650044.html
SOURCE ImaginAb, Inc.
